Desmopressin (DDAVP, Stimate)
Synthetic vasopressin (ADH) analog used in diabetes insipidus, nocturnal enuresis, and certain bleeding disorders.
At a glance
What it is: Synthetic vasopressin (ADH) analog used in diabetes insipidus, nocturnal enuresis, and certain bleeding disorders..
Primary research applications:
- Central diabetes insipidus
- Nocturnal enuresis (selected pediatric and adult)
- Mild hemophilia A and von Willebrand disease (type 1)
Editorial summary: Desmopressin is one of the most widely prescribed therapeutic peptides — a synthetic vasopressin analog with selective antidiuretic activity that has been in clinical use since 1972. Its long track record across multiple indications makes it a frequent reference for what successful peptide drug development looks like.
- Class / structure
- Synthetic 9-amino-acid vasopressin analog (D-arginine; deamination at position 1)
- Half-life
- ≈ 75 minutes (intravenous); longer for intranasal / oral formulations
- First described
- 1967
- Regulatory status
- FDA-approved (1972)
What is Desmopressin?
Desmopressin (1-deamino-8-D-arginine vasopressin, DDAVP) is a synthetic analog of arginine vasopressin engineered for selective V2 receptor activity (antidiuretic) with minimal V1 receptor activity (vasopressor).
Discovery and development
Desmopressin was synthesized by Manfred Zaoral and colleagues in Czechoslovakia in 1967 as part of systematic vasopressin analog research. It was approved by the FDA in 1972 and has been in continuous clinical use for over five decades. Its molecular design — deamination at position 1 and substitution of D-arginine at position 8 — selectively retains antidiuretic activity while greatly reducing pressor effects of native vasopressin.
Mechanism of action
V2 receptor activation in the renal collecting duct increases water permeability via aquaporin-2 trafficking, producing antidiuresis. Desmopressin also stimulates release of von Willebrand factor and factor VIII from endothelial Weibel-Palade bodies — the basis of its hemostatic effect in mild hemophilia A and type 1 von Willebrand disease.[1]
Pharmacokinetics
Desmopressin is available in intravenous, intranasal, oral, and sublingual formulations. Bioavailability varies considerably (intranasal ~10%, oral ~0.1–0.16%, sublingual higher than oral). Antidiuretic effect duration is several hours; bleeding-disorder hemostatic effects persist longer.
What the research shows
The peer-reviewed literature on Desmopressin is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Treats central diabetes insipidus | Decades of clinical experience | Supported |
| Reduces nocturnal enuresis | Multiple controlled trials | Supported |
| Provides hemostatic benefit in mild hemophilia A | Established | Supported |
Reported user experiences
How the research describes administration
Available in IV, intranasal, oral tablet, sublingual, and subcutaneous forms. Selection depends on indication, route preferred, and patient population.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Desmopressin is a foundational peptide therapeutic — a textbook case of how rational analog design (V2 selectivity from D-arginine substitution and deamination) can produce a drug that has been clinically essential for half a century. Its breadth of use across endocrine, urologic, and hematologic indications speaks to the underlying biology.
Frequently asked questions
Is desmopressin the same as vasopressin?
It is a selective analog. Native arginine vasopressin has both antidiuretic (V2) and pressor (V1) activity; desmopressin is engineered for nearly pure antidiuretic activity.
Why is desmopressin used in von Willebrand disease?
It triggers release of stored von Willebrand factor and factor VIII from endothelial cells, transiently raising plasma levels enough to support hemostasis in mild disease.
References
- Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med. 2004;351(7):683-694. https://pubmed.ncbi.nlm.nih.gov/15306670/
- Robertson GL. Diabetes insipidus: differential diagnosis and management. Best Pract Res Clin Endocrinol Metab. 2016;30(2):205-218. https://pubmed.ncbi.nlm.nih.gov/27156761/